Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Bullboard Posts
Comment by StuinSeaon Dec 11, 2018 2:52pm
100 Views
Post# 29098848

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:THERAPIX UPDATE TODAY

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:THERAPIX UPDATE TODAY

For the life of me I can't make this smaller, but it confirms your thinking.




Fundy13 wrote: Teh LOI was for $48million US and the HUGE SP was to be calculated using a 20 day moving average for the 20 days prior to the closing of the deal, which was expected to be sometime in January.  So the deal could not have been done at $0.39.
After the definitive agreement woudl have been signed, then the 20 day average woudl start.  So neither TRPX nor HUGE would know the number of shares of HUGE TRPX shareholders woudl end up with.  I am fairly certain that HUGE is looking to change that part of the deal and they should.  the SP is far to volitle to make a deal that way, they could sign and SP drop backt o $0.10 and then they are giving away half the company.
The deal needs to be for a set number of shares based on current SP, we will see if TRPX is ok with that.  TRPX has another deal in their back pocket with CURE, so they may not be willing to budge much from the LOI.  They also may recieve financial compensation from HUGE for breaking the terms of the binding LOI.  They did not say in the PR but binding LOI come with penalties from breaking the terms of the agreement, that is what seperates a binding LOI from a regular LOI.


 

Bullboard Posts